NRIX vs. XBI

In the year-to-date period, NRIX achieves a -43.58% return, which is significantly lower than XBI's -12.06% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Nurix Therapeutics, Inc. (NRIX) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current NRIX Sharpe Ratio is -0.49, which is comparable to the XBI Sharpe Ratio of -0.39. The chart below compares the historical Sharpe Ratios of NRIX and XBI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

NRIX has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.17%.

The maximum NRIX drawdown since its inception was -91.53%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for NRIX and XBI.

Nurix Therapeutics, Inc. (NRIX) has a higher volatility of 20.12% compared to SPDR S&P Biotech ETF (XBI) at 10.41%. This indicates that NRIX's price experiences larger fluctuations and is considered to be riskier than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.